We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses (ANRS139 TRIO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00460382
Recruitment Status : Completed
First Posted : April 13, 2007
Last Update Posted : September 17, 2010
Merck Sharp & Dohme Corp.
Janssen-Cilag Tibotec
Information provided by:
French National Agency for Research on AIDS and Viral Hepatitis

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Primary Completion Date : March 2008
  Study Completion Date : September 2009

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 August 11, 2011 September 14, 2011
2 December 21, 2011 January 20, 2012
3 July 16, 2012 August 17, 2012
4 November 6, 2012 December 3, 2012
5 July 17, 2013  
6 January 7, 2014 February 21, 2014